Table 1. . Selected studies of induction chemotherapy regimens in older patients with acute lymphoblastic leukemia.
| Year† | Group/study | Age | No. of patients | CR rate % | Induction/early death rate % | OS rate % | ||
|---|---|---|---|---|---|---|---|---|
| 1 year | 3 years | 5 years | ||||||
| 2000 | MD Anderson [69] | >60 | 44 | 79 | 16 | 17 | ||
| 2001 | SWOG 8419 [70] | 50–84 | 85 | 41 | 37 | <10 | ||
| 2002 | GIMEMA 0208 [71] | 50–60 | 121 | 68 | – | 15 | ||
| 2005 | CALGB [72] | >60 | 129 | 57 | – | 12 | ||
| 2007 | PETHEMA ALL96‡ [17] | 56–67 | 33 | 58 | 36 | 39 | ||
| 2008 | SWOG 9400 [73] | 50–65 | 43 | 63 | – | 23 | ||
| 2008 | EWALL [74] | 56–73 | 40 | 85 | 0 | 61 | ||
| 2012 | MRC UKALL XII/ECOG2993 [14] | 55–64 | 100 | 70 | 18 | 21 | ||
| 2012 | GMALL‡ [18] | 55–85 | 268 | 76 | 14 | 23 | ||
| 2016 | Multicenter [39] | 51–72 | 30 | 67 | 3 | 63 | ||
| 2016 | PETHEMA, ALLOLD07‡ [75] | 56–79 | 54 | 74 | 13 | 50 | ||
†Year of study publication.
‡Included patients with Ph-negative ALL only.
ALL: Acute lymphoblastic leukemia; CR: Complete response; OS: Overall survival; Ph: Philadelphia.